IL-21 Protein, Human

IL-21 Protein, Human is a class 1 cytokine, which is produced by activated CD4⁺ T cells. IL-21 Protein stimulation of T cells, B cells and NK cells leads to enhanced proliferation and mature effector function.

Interleukin-21 (IL-21) is a pleiotropic cytokine that has key functions in both the innate and adaptive immunity and the regulation of autoimmunity. IL-21 has a range of activities likely to potentiate antitumor immunoresponses. IL-21 has a role as a single agent in the treatment of melanoma. IL-21 also has significant activity against various types of cancer in combination with monoclonal antibodies or signaling inhibitors^[1]. Recombinant human interleukin-21 (rIL-21), a human recombinant interleukin, with Cetuximab, a monoclonal antibody, targeting the epidermal growth factor receptor^[2].

1.The ED₅₀ is <0.5 ng/mL as measured by Mino cells, corresponding to a specific activity of >2.0 × 10⁶ units/mg.
2.Measured by its binding ability in a functional ELISA. Immobilized Human IL-21R at 5 μg/mL (100 μL/well) can bind Human IL-21. The ED₅₀ for this effect is 5.056 ng/mL.
3.Measured by its ability to enhance IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED₅₀ for this effect is 6.707 ng/mL.

• 
  Measured by its ability to enhance IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED₅₀ for this effect is 6.707 ng/mL, corresponding to a specific activity is 1.491×10⁵ U/mg.

Human

E. coli

Tag Free

Q9HBE4-1 (Q32-S162)

59067  [NCBI]

Partial

QDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS

Approximately 15.4-18 kDa, based on SDS-PAGE under reducing conditions.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

1.Lyophilized from a 0.22 μm filtered solution of PBS.
2.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 5% trehalose, 5% mannitol, 0.01% Tween 80.
3.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Davis ID, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009 Mar 15;15(6):2123-9.  [Content Brief]

  [2]. Steele N, et al. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer. 2012 Feb 28;106(5):793-8.  [Content Brief]